These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 20716022

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Discovery of a new class of non-imidazole oxazoline-based histamine H(3) receptor (H(3)R) inverse agonists.
    Célanire S, Wijtmans M, Christophe B, Collart P, de Esch I, Dassesse D, Delaunoy C, Denonne F, Durieu V, Gelens E, Gillard M, Lallemand B, Lamberty Y, Lebon F, Nicolas JM, Quéré L, Snip E, Vanbellinghen A, Van Houtvin N, Verbois V, Timmerman H, Talaga P, Leurs R, Provins L.
    ChemMedChem; 2009 Jul; 4(7):1063-8. PubMed ID: 19405064
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Histamine H3 receptor antagonists/inverse agonists: Where do they go?
    Ghamari N, Zarei O, Arias-Montaño JA, Reiner D, Dastmalchi S, Stark H, Hamzeh-Mivehroud M.
    Pharmacol Ther; 2019 Aug; 200():69-84. PubMed ID: 31028835
    [Abstract] [Full Text] [Related]

  • 11. [The histaminergic system: a target for innovative treatments of cognitive deficits].
    Motawaj M, Burban A, Davenas E, Gbahou F, Faucard R, Morisset S, Arrang JM.
    Therapie; 2010 Aug; 65(5):415-22. PubMed ID: 21144476
    [Abstract] [Full Text] [Related]

  • 12. Diamine derivatives containing imidazolidinylidene propanedinitrile as a new class of histamine H3 receptor antagonists. Part I.
    Sasho S, Seishi T, Kawamura M, Hirose R, Toki S, Shimada JI.
    Bioorg Med Chem Lett; 2008 Apr 01; 18(7):2288-91. PubMed ID: 18353639
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Neuropsychiatry of Histaminergic Circuits: Potential Role of Novel H3 Receptor Selective Antagonist/Inverse Agonist Pitolisant in Prader-Willi Syndrome.
    Freitas B, Teodoro TP.
    Psychopharmacol Bull; 2024 Jul 08; 54(3):103-107. PubMed ID: 38993657
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Therapeutic potential of histamine H3 receptor antagonists in dementias.
    Chazot PL.
    Drug News Perspect; 2010 Mar 08; 23(2):99-103. PubMed ID: 20369074
    [Abstract] [Full Text] [Related]

  • 18. Histamine and schizophrenia.
    Arrang JM.
    Int Rev Neurobiol; 2007 Mar 08; 78():247-87. PubMed ID: 17349864
    [Abstract] [Full Text] [Related]

  • 19. The evolution of histamine H₃ antagonists/inverse agonists.
    Lebois EP, Jones CK, Lindsley CW.
    Curr Top Med Chem; 2011 Mar 08; 11(6):648-60. PubMed ID: 21261594
    [Abstract] [Full Text] [Related]

  • 20. Mechanistic characterization of S 38093, a novel inverse agonist at histamine H3 receptors.
    Sors A, Panayi F, Bert L, Favale D, Nosjean O, Audinot V, Arrang JM, Buisson B, Steidl E, Delbos JM, Huhtala T, Kontkanen O, Chollet AM, Casara P, Lestage P.
    Eur J Pharmacol; 2017 May 15; 803():11-23. PubMed ID: 28336400
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.